What the McKinsey AI Playbook Misses for Pre-Revenue Biotech

What the McKinsey Playbook Actually Says

McKinsey’s published work on AI in pharma articulates a recognizable framework. The framework is not a single document; it emerges from a series of articles published over 2023-2026. The core elements:

Value pools across the value chain. McKinsey identifies value pools in commercial functions ($18-30 billion), biopharmaceutical operations ($4-7 billion), and the broader value chain. The value pool framing organizes thinking about where AI investment should go.

Use case prioritization by impact and feasibility. The framework prioritizes use cases by their expected value impact and their implementation feasibility. High-impact, high-feasibility use cases get attention first.

Operating model transformation. McKinsey’s 2026 analysis “How pharma is rewriting the AI playbook” emphasizes that successful organizations are reworking their operating models to embed AI across the value chain, not layering AI on top of existing processes.

Scaling across the enterprise. The “Scaling gen AI in the life sciences industry” analysis emphasizes moving from isolated pilots to enterprise-wide deployment with consistent governance, infrastructure, and capability.

Talent and capability investment. The framework articulates the importance of building AI talent at scale, including both technical AI capability and the broader capability for business leaders to operate in an AI-enabled environment.

Governance and risk management. Cross-functional governance covering AI strategy, deployment, and risk management is positioned as a precondition for sustainable scaling.

The framework is internally coherent and largely right for the organizations it advises. The question is how well it travels to pre-revenue biotechs operating under fundamentally different constraints.

Five Assumptions That Break Down at Pre-Revenue Scale

The McKinsey framework rests on assumptions that hold for large-cap pharma and break down for pre-revenue biotechs. The five most consequential breakdowns:

Revenue baseline for value measurement. McKinsey’s value pool framework assumes commercial revenue against which AI value can be measured. Pre-revenue biotechs have no commercial revenue, which means the value measurement framework has to be reconstructed around milestone progress, capital efficiency, and platform validation rather than around revenue impact.

Multi-year strategic horizons. The McKinsey framework assumes multi-year strategic horizons that justify multi-year investments. Pre-revenue biotechs operate on milestone cadences that are typically twelve to eighteen months. AI investments that pay off in three to five years are difficult to justify when the organization may not survive to capture the payoff.

Operating model scale. The operating model transformations McKinsey recommends — embedding AI across the value chain, building dedicated AI functions, establishing cross-functional governance organizations — assume organizational scale that pre-revenue biotechs do not have. A 200-person biotech cannot build a dedicated AI function; it can dedicate one or two people, at most, before the organization is meaningfully understaffed in critical functions.

Capital availability. The framework assumes capital availability for sustained investment in AI capability. Pre-revenue biotechs have capital available to deploy toward IND-enabling work, clinical milestones, and platform validation. Capital deployed toward AI capability is capital not deployed toward those priorities; the tradeoff is direct.

Talent acquisition leverage. The framework’s talent strategy assumes the ability to attract and retain AI talent at scale. Pre-revenue biotechs compete for AI talent against large-cap pharma, against well-capitalized AI companies, and against the broader tech industry. The talent acquisition leverage is materially weaker; building AI capability through hiring is harder than the framework assumes.

These assumption breakdowns do not invalidate the McKinsey framework; they signal that the framework needs adaptation rather than direct application. The question is what adaptations preserve the strategic insights while accommodating the pre-revenue reality.

The Value Realization Problem

The value realization problem is the most consequential of the assumption breakdowns. McKinsey’s value pool framework is constructed in commercial revenue terms; for pre-revenue biotechs, the framework has to be reconstructed in different units.

The right units for pre-revenue biotech AI value are: milestone acceleration, capital efficiency, and platform value enhancement.

Milestone acceleration. AI investments should be measured by how much they accelerate the next milestone the biotech is working toward. Days saved on a regulatory submission, weeks saved on clinical trial setup, months saved on IND-enabling work — these are the relevant units. The acceleration may be modest, but for a biotech whose milestone cadence is the binding constraint on its valuation, even modest acceleration is consequential.

Capital efficiency. AI investments should be measured by how much they reduce the capital required to reach the next milestone. Reduced consulting spend, reduced internal headcount needs, reduced regulatory iteration cycles — these translate into capital efficiency. The efficiency may not show up as a dollar saved; it may show up as a capability the biotech can absorb without an incremental hire.

Platform value enhancement. AI investments should be measured by how much they enhance the value of the platform thesis the biotech is selling. Investors and acquirers value platforms more highly when the platforms include differentiated AI capabilities; the AI investment can be a direct contributor to valuation. This is the most strategically important value framing for pre-revenue biotech, even though it is hardest to quantify.

The McKinsey framework can be adapted to pre-revenue biotech by translating its value pool concepts into these alternative units. The strategic insight — that AI value should be measured rigorously and prioritized by impact — survives the translation. The specific quantification has to change.

The Operating Model Problem

McKinsey’s operating model recommendations assume scale that pre-revenue biotechs do not have. The recommendations have to be reduced to a scale appropriate to the organization without losing their strategic intent.

The adaptations preserve the strategic intent of the McKinsey recommendations while reducing the operational footprint to what a pre-revenue biotech can actually staff and sustain. The discipline is in resisting the temptation to import the larger pattern without adaptation; programs that try to operate the full McKinsey model at pre-revenue scale consistently fail because the staff and capital are not available.

The Talent and Capability Problem

The talent strategy in McKinsey’s framework is one of the most consequential elements and one of the hardest to translate to pre-revenue scale. The framework assumes the ability to attract and retain AI talent in numbers that pre-revenue biotechs cannot reasonably target.

The Pistoia Alliance survey referenced in industry analyses indicates that 44% of pharma organizations cite lack of skills as a major barrier to AI adoption. The skills gap is real at every scale, but it is most acute for pre-revenue biotechs that cannot offer the compensation, the equity upside (at least until late-stage), or the project breadth that larger organizations offer.

The adaptations that work:

Hire for breadth over depth. A 500-person biotech that hires three deep specialists in narrow AI subfields will be poorly served. Hiring for breadth — generalists who can operate across data engineering, MLOps, and AI application engineering — produces more value at this scale.

Partner with external specialists for deep capability. Where deep specialized capability is needed (rigorous bias and fairness assessment, advanced retrieval architectures, sophisticated MLOps tooling), the partnership model works better than in-house hiring at pre-revenue scale. The partnership is a way to acquire specialist capability without sustaining the specialist’s full cost.

Build internal capability through upskilling rather than hiring. Existing staff who develop AI capability through deliberate training are more valuable than newly-hired specialists at this scale, because the existing staff bring domain expertise that the new hires lack. Training programs that build AI capability in existing data analysts, biostatisticians, and clinical operations leads can produce more value than equivalent hiring spend. The IntuitionLabs analysis of workforce development for generative AI in life sciences documents the scale at which leading pharmas are investing in workforce upskilling.

Treat AI capability as everyone’s responsibility, not just the platform team’s. The platform team owns the infrastructure; the use case owners own the application of AI to their workflows. This split of ownership scales much better than concentrating all AI responsibility in the platform team.

An Alternative Frame for Pre-Revenue Biotech

Pulling the adaptations together produces an alternative frame for AI strategy in pre-revenue biotech. The frame has six elements.

1. Milestone-anchored value framing. Every AI investment is justified against a specific milestone it accelerates, a specific capital efficiency it produces, or a specific platform value it enhances. Investments that cannot be tied to one of these anchors are presumptively wrong for the stage.

2. Buy-first, partner-second, build-third. The default sequencing for AI capabilities matches the build/partner/buy framework calibrated for pre-commercial biotech. Capabilities are bought from vendors when commodity, partnered with specialists when platform-relevant, and built in-house only when scientifically differentiating.

3. Workflow-embedded AI in priority workflows. AI capabilities are integrated into the existing tools used in the two or three priority workflows where they can produce milestone value. Expansion happens as the priority workflows demonstrate success.

4. Small platform team with external augmentation. The internal platform team is sized for the foundational architecture (typically 3-7 people for a 500-person biotech), with external partnership augmentation for specialized capability the team cannot reasonably staff.

5. Lightweight governance with cross-functional steering. The governance discipline is real but sized to the organization. A single cross-functional steering committee with monthly cadence and defined decision rights is typically adequate; multi-tier governance structures are overhead the organization cannot sustain.

6. Upskilling-centered capability building. AI capability is built primarily through deliberate upskilling of existing staff, with targeted hiring for capabilities that genuinely cannot be developed through upskilling. The upskilling investment compounds over time and produces capability that hires would not produce.

The alternative frame is not anti-McKinsey; it is an adaptation of the McKinsey strategic intent to the scale at which pre-revenue biotechs operate. The strategic insights — disciplined value framing, prioritized use cases, operating model alignment, talent investment, governance discipline — all survive the adaptation. The specific implementations change because the constraints are different.

What to Take From McKinsey and What to Leave

Pre-revenue biotech leaders reading McKinsey’s pharma AI work can extract substantial value if they are deliberate about what to take and what to leave.

Take the strategic insights. The framework’s strategic insights — that AI value is concentrated in specific value pools, that operating model alignment matters more than technology choices, that governance is a precondition for scaling, that talent investment is foundational — are largely right at every scale. These insights translate to pre-revenue biotech with appropriate adaptation.

Take the use case prioritization discipline. The discipline of prioritizing AI investments by expected value impact and implementation feasibility is right at every scale. The specific use cases will differ, but the discipline of prioritization survives.

Take the warning against pilot proliferation. McKinsey’s recurring observation that organizations get stuck at the pilot stage applies as forcefully to pre-revenue biotechs as to large pharma. The warning to push past pilots into production, with disciplined scaling, is universally applicable.

Leave the multi-year transformation framing. Multi-year transformation programs are not feasible at pre-revenue scale and do not survive the milestone cadence. Translate the strategic intent into the milestone cadence the biotech actually operates on.

Leave the dedicated function recommendations. Dedicated AI functions are not staffable at pre-revenue scale. The strategic intent of cross-functional integration can be preserved through lightweight governance and explicit decision rights.

Leave the comprehensive talent buildout. Hiring AI talent at McKinsey-recommended scale is not achievable at pre-revenue scale and is rarely the right investment even when capital is available. Upskilling, partnerships, and targeted hiring produce better outcomes.

The discipline is in recognizing that the McKinsey framework is a strategic resource, not a tactical playbook. Pre-revenue biotechs that mine it for strategic insight while adapting the tactics to their constraints get the most value. Pre-revenue biotechs that try to operate the framework at face value consistently struggle.

The acquirer’s perspective on biotech AI investment

One strategic dimension worth emphasizing: pre-revenue biotechs eventually face acquisition or partnership decisions, and the AI investments they have made affect those decisions. Acquirers and partners evaluate biotech AI capability with two questions. First, does the AI capability genuinely enhance the platform value, or is it window dressing? Second, can the AI capability be integrated into the acquirer’s existing infrastructure, or does it depend on bespoke architecture that the acquirer would have to rebuild?

The implication is that biotechs whose AI investments produce demonstrable platform value enhancement, built on architecture that travels reasonably across acquirer environments, are positioned to capture more value in acquisition or partnership transactions than biotechs whose AI investments are either superficial or architecturally idiosyncratic. The McKinsey framework, applied at scale, sometimes produces investments that look impressive in isolation but do not translate well across organizational boundaries. The alternative frame for pre-revenue biotech, with its emphasis on workflow embedding, buy-first model layers, and lightweight governance, tends to produce AI capability that is both genuinely valuable and reasonably portable.

The risk of importing patterns that the organization cannot operate

A final caution: the risk of importing patterns that the organization cannot operate is real and underappreciated. Pre-revenue biotech leaders sometimes import the McKinsey framework with the intention of growing into it as the organization scales. The intention is reasonable but rarely succeeds. The patterns require organizational scale to operate; without the scale, they atrophy. Leaders who import the patterns prematurely often end up with documentation that describes a transformation that did not happen, governance bodies that meet rarely and decide little, and dedicated functions that are staffed at one or two people and unable to deliver on their charter.

The better strategy is to operate at the scale appropriate to the current organization and to grow into larger patterns deliberately as the scale supports them. The McKinsey framework is a useful map of the destination; it is not the route the organization should take from its current position.

References & Sources